The GRIN2B gene is crucial for normal brain function, playing a key role in the development of the nervous system and synaptic plasticity. Mutations in this gene have been linked to early infantile epileptic encephalopathy type 27 (EIEE27), a severe condition characterized by frequent seizures, developmental delays, and various neurological issues beginning in infancy.
DNA Labs UAE offers a specialized genetic test designed to identify mutations in the GRIN2B gene associated with EIEE27. This test is an important tool for diagnosing the condition, enabling early intervention and personalized treatment plans to manage symptoms and improve quality of life for affected individuals.
The cost of the GRIN2B Gene Early Infantile Epileptic Encephalopathy Type 27 Genetic Test at DNA Labs UAE is 4400 AED. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the lab to detect any genetic abnormalities in the GRIN2B gene. Results from this test can provide crucial information for families and healthcare providers, guiding decisions about care and support for individuals with EIEE27.
The WWOX gene plays a significant role in early infantile epileptic encephalopathy type 28 (EIEE28), a condition characterized by severe seizures and developmental delays in infancy. Genetic testing for mutations in the WWOX gene is crucial for the diagnosis and management of EIEE28. DNA Labs UAE offers a specialized genetic test to identify these mutations, providing essential information for families and healthcare providers. The test, priced at 4400 AED, involves analyzing the patient's DNA to detect abnormalities in the WWOX gene that may be responsible for the condition. This genetic testing is a vital step towards understanding the specific cause of the epilepsy and encephalopathy, allowing for tailored treatment plans and support for affected individuals and their families.
The AARS1 gene plays a crucial role in the proper functioning of the human body by coding for alanyl-tRNA synthetase, an enzyme involved in protein synthesis. Mutations in this gene have been linked to early infantile epileptic encephalopathy type 29 (EIEE29), a severe form of epilepsy that manifests in the first few months of life. This condition is characterized by frequent seizures, developmental delays, and, in many cases, other neurological impairments.
To diagnose this condition accurately and early, genetic testing targeting the AARS1 gene can be performed. DNA Labs UAE offers a specialized genetic test for EIEE29, providing a crucial diagnostic tool for affected families. The test involves analyzing the patient's DNA to identify mutations in the AARS1 gene that are known to cause the disorder. This information can aid in the development of a tailored treatment plan, potentially improving outcomes for the affected individual.
The cost of the AARS1 Gene Early Infantile Epileptic Encephalopathy Type 29 Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect the specific genetic alterations associated with this condition, offering invaluable insights for affected families and their healthcare providers.
The SLC25A22 gene is associated with early infantile epileptic encephalopathy type 3 (EIEE3), a severe form of epilepsy that begins in infancy. This condition is characterized by frequent seizures and significant neurodevelopmental delay. The SLC25A22 gene plays a crucial role in the proper functioning of mitochondria, the energy-producing components of cells, and mutations in this gene can disrupt brain activity, leading to the symptoms observed in EIEE3.
Genetic testing for mutations in the SLC25A22 gene is a critical step in diagnosing EIEE3, enabling early intervention and tailored management plans for affected infants. DNA Labs UAE offers a comprehensive genetic test for the SLC25A22 gene to help identify the presence of mutations associated with early infantile epileptic encephalopathy type 3. The test cost is 3200 AED and is conducted with state-of-the-art technology to ensure accurate and reliable results. By undergoing this test, families can gain valuable insights into the genetic underpinnings of the condition, which can inform treatment decisions and provide a clearer prognosis for affected infants.
The SIK1 gene plays a crucial role in the development and function of the nervous system. Mutations in this gene have been associated with Early Infantile Epileptic Encephalopathy Type 30 (EIEE30), a severe form of epilepsy that emerges in the first few months of life. This condition is characterized by frequent seizures and significant developmental delays, presenting a profound challenge for affected individuals and their families.
DNA Labs UAE offers a specialized genetic test to identify mutations in the SIK1 gene, providing crucial information for the diagnosis of EIEE30. The test is an important tool for clinicians in confirming the diagnosis, which can then guide treatment strategies and genetic counseling. Understanding the genetic basis of the condition can also help in predicting the course of the disease and in some cases, may inform treatment options.
The cost of the SIK1 gene test for Early Infantile Epileptic Encephalopathy Type 30 at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect mutations in the SIK1 gene, providing families and healthcare providers with essential information for managing the condition. Given the complexity of EIEE30 and the significant impact it has on affected individuals, this genetic test represents a critical step in the journey towards better care and outcomes.
The DNM1 Gene Early Infantile Epileptic Encephalopathy Type 31 Genetic Test is a specialized diagnostic examination offered by DNA Labs UAE, designed to detect mutations in the DNM1 gene, which have been associated with Early Infantile Epileptic Encephalopathy Type 31 (EIEE31). This condition is a severe form of epilepsy that manifests in infancy and is characterized by frequent seizures and significant developmental delays. The test plays a crucial role in the early identification of this genetic disorder, enabling healthcare providers to initiate appropriate treatment and management strategies as early as possible.
The testing process involves collecting a DNA sample from the patient, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for any genetic abnormalities in the DNM1 gene. Positive identification of mutations can help in confirming the diagnosis of EIEE31, facilitating a better understanding of the condition's progression and the potential response to various treatment options.
The cost of the DNM1 Gene Early Infantile Epileptic Encephalopathy Type 31 Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect the specific genetic mutation associated with this condition. By choosing DNA Labs UAE for this critical testing, patients and their families gain access to advanced genetic testing technology and expertise, ensuring accurate and reliable results that can significantly impact the management and outcome of the condition.
The KCNA2 gene early infantile epileptic encephalopathy type 32 genetic test is a specialized diagnostic procedure aimed at identifying mutations in the KCNA2 gene, which are associated with early infantile epileptic encephalopathy type 32 (EIEE32). This condition is a severe form of epilepsy that manifests in the first few months of life, characterized by frequent seizures and significant developmental delays. The test plays a crucial role in the early detection and management of this condition, allowing for tailored treatment plans that can improve the quality of life for affected individuals.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test involves analyzing the patient's DNA to look for specific genetic alterations in the KCNA2 gene that are linked to EIEE32. This state-of-the-art lab ensures accurate and reliable results, leveraging advanced genetic sequencing technologies.
The cost of the KCNA2 gene early infantile epileptic encephalopathy type 32 genetic test at DNA Labs UAE is set at 4400 AED. This investment covers the comprehensive process of sample collection, DNA extraction, sequencing, and expert analysis, providing families with crucial information regarding the genetic underpinnings of the condition. Early diagnosis through this test can significantly impact the management strategies for affected infants, paving the way for interventions that can mitigate the severity of symptoms and promote better developmental outcomes.
The EEF1A2 gene is associated with a rare neurological disorder known as early infantile epileptic encephalopathy type 33 (EIEE33). This condition is characterized by severe seizures that begin in infancy, often accompanied by developmental delays and various neurological challenges. The EEF1A2 gene plays a crucial role in protein synthesis within cells, and mutations in this gene can disrupt normal brain function, leading to the symptoms observed in EIEE33.
To diagnose this condition and potentially guide treatment options, genetic testing can be performed to identify mutations in the EEF1A2 gene. In the UAE, DNA Labs UAE offers a specific genetic test for the EEF1A2 gene, catering to families and individuals seeking answers about this rare epileptic disorder. The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory for the presence of mutations in the EEF1A2 gene.
The cost of the EEF1A2 gene test at DNA Labs UAE is 4400 AED. This price includes the collection of the sample, the genetic analysis, and a comprehensive report that interprets the findings. This report can be an invaluable tool for healthcare providers in diagnosing EIEE33, understanding its severity, and potentially guiding treatment decisions. Families affected by early infantile epileptic encephalopathy or those with a history of the condition may consider this test to gain more insight into their medical situation and to inform their healthcare decisions.
The STXBP1 gene is associated with early infantile epileptic encephalopathy type 4 (EIEE4), a severe neurological disorder characterized by early-onset seizures and developmental delays. Genetic testing for mutations in the STXBP1 gene is crucial for diagnosing this condition, enabling early intervention and personalized management strategies for affected individuals.
DNA Labs UAE offers a comprehensive genetic test targeting the STXBP1 gene to identify mutations that may lead to EIEE4. The test is designed to provide accurate and reliable results, which are essential for the diagnosis and treatment planning of this epileptic encephalopathy. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the sophisticated technology employed.
By opting for this genetic test, families and healthcare providers can gain valuable insights into the genetic underpinnings of the condition, facilitating informed decisions about care and support for those affected by EIEE4.
The GUF1 gene is associated with early infantile epileptic encephalopathy type 40 (EIEE40), a severe form of epilepsy that emerges in the first months of life. This condition is characterized by frequent seizures that are resistant to treatment, developmental delays, and sometimes other neurological issues. Genetic testing for mutations in the GUF1 gene is crucial for diagnosing EIEE40, enabling targeted treatment plans and providing families with essential prognostic information.
At DNA Labs UAE, a specialized test is available for identifying mutations in the GUF1 gene that are linked to early infantile epileptic encephalopathy type 40. This test is an important tool for clinicians in the diagnosis and management of this challenging condition. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify mutations in the GUF1 gene. By offering this test, DNA Labs UAE supports healthcare providers and families in the early detection and intervention of EIEE40, potentially improving outcomes for affected infants.
